Indication from Summary of Product Characteristics
PIQRAY is indicated in combination with
fulvestrant for the treatment of
postmenopausal women, and men, with hormone
receptor (HR)‐positive, human
epidermal growth factor receptor 2
(HER2)‐negative, locally advanced or
metastatic breast cancer with a PIK3CA
mutation after disease progression following
endocrine therapy as monotherapy.
References:1. Mosele F,
Outcome and molecular landscape of patients with
PIK3CA-mutated metastatic breast cancer.
Ann Oncol. 2020;31(3):377-386.
2. The Cancer Genome
Atlas Network. Comprehensive molecular portraits of
human breast tumours.
3. Chalhoub C,Baker SJ. PTEN and
the PI3-kinase pathway in cancer.
Annu Rev Pathol. 2009;4:127-150.
EU Summary of Product Characteristics. Novartis;
5. André F,Ciruelos E,Rubovszky G,et al. Alpelisib
for PIK3CA-mutated, hormone receptor-positive
advanced breast cancer.
N Engl J Med. 2019;380(20):1929-1940.
This is an international site for PIQRAY®
(alpelisib) and is intended for healthcare professionals
outside the US.
The information on the site is not
country-specific, and may contain
information that is outside the
approved indications in the country
in which you are located. Please
contact your local Novartis
representative for the latest
information specific to your
country. Please contact your local
Novartis representative for local
prescribing information via
IMPORTANT: The information
on this website is based on
the European Summary of
Product Characteristics (EU
US HCPs & Other
Below is a list of the countries
that host a PIQRAY website based
on local label and in a local
language. They are intended for
healthcare professionals (HCPs)
only. If you are an HCP from one
of the countries listed below,
click on your country's link to
be redirected to your country's